BAARERSTRASSE 14, ZUG, V8
Prices Upsized Convertible Senior Notes Offering
Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Other Events
Provides Business Update and Reports Third Quarter 2025 Financial Results
CRISPR Therapeutics Files Prospectus Supplement for $600 Million Offering
Provides Business Update and Reports Second Quarter 2025 Financial Results
Amendments to Articles of Incorporation or Bylaws, Shareholder votes
FY 2024
Q3
Q2
Q1
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
S-3ASR
PRE 14A
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Submission Upload
Correspondence